The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bruker (BRKR – Research Report), Inspire Medical Systems (INSP – Research Report) and Pfizer (PFE – Research Report) with bullish sentiments.
Bruker (BRKR)
Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Bruker today and set a price target of $95.00. The company’s shares closed last Thursday at $94.27, close to its 52-week high of $94.86.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bruker with a $87.88 average price target.
See today’s best-performing stocks on TipRanks >>
Inspire Medical Systems (INSP)
In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Inspire Medical Systems, with a price target of $265.00. The company’s shares closed last Thursday at $195.23.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inspire Medical Systems with a $250.67 average price target, a 25.6% upside from current levels. In a report issued on March 19, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $250.00 price target.
Pfizer (PFE)
In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Pfizer. The company’s shares closed last Thursday at $27.66, close to its 52-week low of $25.61.
According to TipRanks.com, Toung is a 5-star analyst with an average return of
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $31.44.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BRKR:
As previously reported, Argus downgraded Pfizer (PFE) to Hold from Buy. The company is faced with near-term headwinds to its top-line growth as it has guided to 2024 3%-5% revenue
Argus downgraded Pfizer to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts
Argus שינו את המלצתם לגבי Pfizer מ”קנייה” ל”החזקה”.